Protagonist Therapeutics, Inc.
PTGX
$56.25
$0.040.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.09% | -88.89% | 184.40% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.09% | -88.89% | 184.40% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 33.09% | -88.89% | 184.40% | -- | -- |
| SG&A Expenses | 11.77% | -21.27% | 11.20% | 32.58% | 2.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.77% | -2.08% | 18.69% | 20.36% | 1.43% |
| Operating Income | -8.37% | -109.36% | 450.05% | -8.16% | 8.41% |
| Income Before Tax | -10.57% | -105.53% | 388.98% | 1.39% | 18.64% |
| Income Tax Expenses | 125.44% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.57% | -105.62% | 381.70% | 2.62% | 20.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.57% | -105.62% | 381.70% | 2.62% | 20.40% |
| EBIT | -8.37% | -109.36% | 450.05% | -8.16% | 8.41% |
| EBITDA | -8.26% | -109.23% | 444.70% | -8.25% | 8.46% |
| EPS Basic | -9.63% | -105.43% | 366.67% | 6.70% | 26.28% |
| Normalized Basic EPS | -6.74% | -105.35% | 373.77% | 5.52% | 24.66% |
| EPS Diluted | -10.00% | -105.83% | 351.31% | 6.90% | 26.47% |
| Normalized Diluted EPS | -6.74% | -105.59% | 354.97% | 5.52% | 24.66% |
| Average Basic Shares Outstanding | 3.60% | 3.46% | 3.21% | 4.37% | 7.98% |
| Average Diluted Shares Outstanding | 3.60% | -0.99% | 7.46% | 4.37% | 7.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |